Translocations in epithelial cancers

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1796, Issue 2, 2009, Pages 201-215

  Brenner, J Chad ^a,c   Chinnaiyan, Arul M ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ALK; Chimera; COPA; Epithelial; ERG; Gene fusion; HMGA2; MLL; Rearrangement; Translocation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; HIGH MOBILITY GROUP A2 PROTEIN; MEMBRANE PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEAR PROTEIN IN TESTIS; ONCOPROTEIN; PAPILLARY RENAL CELL CARCINOMA PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLEOMORPHIC ADENOMA GENE 1 PROTEIN; PROTEIN BRD4; PROTEIN NTRK1; PROTEIN NTRK3; PROTEIN RET; PROTEIN SLC45A3; PROTEIN TFE3; REACTIVE OXYGEN METABOLITE; SODIUM PHOSPHATE COTRANSPORTER 2B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 4; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX8; TRANSMEMBRANE PROTEASE SERINE 2; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

CARCINOMA; CHIMERA; GENE AMPLIFICATION; GENE FUNCTION; GENE FUSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC REGULATION; HUMAN; KIDNEY CARCINOMA; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NONHUMAN; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THYROID CARCINOMA;

ANIMALS; GENE FUSION; HUMANS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGAN SPECIFICITY; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 70349179401     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.04.005     Document Type: Review

References (202)

1. Von Hansemann D. Ueber asymmetrische zelltheilung in epithelhresbsen und deren biologische bedeutung. Virchows Arch., A Pathol. Anat. 119 (1890) 299-326
2. Boveri T. Zur frage der entstehung maligner tumoren (1914), Jena, Germany
3. Lejeune J., Gautier M., and Turpin R. [Study of somatic chromosomes from 9 mongoloid children.]. C. R. Hebd. Seances Acad. Sci. 248 (1959) 1721-1722
4. Lejeune J., Turpin R., and Gautier M. [Mongolism; a chromosomal disease (trisomy)]. Bull. Acad. Natl. Med. 143 (1959) 256-265
5. Rothfels K.H., and Siminovitch L. An air-drying technique for flattening chromosomes in mammalian cells grown in vitro. Stain Technol. 33 (1958) 73-77
6. Nowell P., and Hungerford D. A minute chromosome in human chronic granulocytic leukemia [Abstract]. Science (New York, N.Y) 132 (1960) 1497
7. Nowell P.C., and Hungerford D.A. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J. Natl. Cancer Inst. 27 (1961) 1013-1035
8. Tough I.M., Court Brown W.M., Baikie A.G., Buckton K.E., Harnden D.G., Jacobs P.A., King M.J., and Mc B.J. Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monogolism. Lancet 1 (1961) 411-417
9. Rowley J.D. Ph1-positive leukaemia, including chronic myelogenous leukaemia. Clin. Haematol. 9 (1980) 55-86
10. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., and Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36 (1984) 93-99
11. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (New York, N.Y) 247 (1990) 1079-1082
12. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
13. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
14. Zech L., Haglund U., Nilsson K., and Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer 17 (1976) 47-56
15. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., and Croce C.M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 7824-7827
16. ar-Rushdi A., Nishikura K., Erikson J., Watt R., Rovera G., and Croce C.M. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science (New York, NY) 222 (1983) 390-393
17. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., and Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318 (1985) 533-538
18. Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann. Genet. 16 (1973) 109-112
19. Gao J., Erickson P., Gardiner K., Le Beau M.M., Diaz M.O., Patterson D., Rowley J.D., and Drabkin H.A. Isolation of a yeast artificial chromosome spanning the 8;21 translocation breakpoint t(8;21)(q22;q22.3) in acute myelogenous leukemia. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 4882-4886
20. Nucifora G., and Rowley J.D. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86 (1995) 1-14
21. Roulston D., Espinosa III R., Nucifora G., Larson R.A., Le Beau M.M., and Rowley J.D. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood 92 (1998) 2879-2885
22. Meyer C., Schneider B., Jakob S., Strehl S., Attarbaschi A., Schnittger S., Schoch C., Jansen M.W., van Dongen J.J., den Boer M.L., Pieters R., Ennas M.G., Angelucci E., Koehl U., Greil J., Griesinger F., Zur Stadt U., Eckert C., Szczepanski T., Niggli F.K., Schafer B.W., Kempski H., Brady H.J., Zuna J., Trka J., Nigro L.L., Biondi A., Delabesse E., Macintyre E., Stanulla M., Schrappe M., Haas O.A., Burmeister T., Dingermann T., Klingebiel T., and Marschalek R. The MLL recombinome of acute leukemias. Leukemia 20 (2006) 777-784
23. F. Mitelman, B. Johansson, F. Mertens, Mitelman Database of Chromosome Aberrations in Cancer, http://cgap.nci.nih.gov/Chromosomes/Mitelman (2008).
24. Martin-Zanca D., Hughes S.H., and Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319 (1986) 743-748
25. Ishizaka Y., Itoh F., Tahira T., Ikeda I., Sugimura T., Tucker J., Fertitta A., Carrano A.V., and Nagao M. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4 (1989) 1519-1521
26. Ishizaka Y., Tahira T., Ochiai M., Ikeda I., Sugimura T., and Nagao M. Molecular cloning and characterization of human ret-II oncogene. Oncogene Res. 3 (1988) 193-197
27. Takahashi M., Ritz J., and Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42 (1985) 581-588
28. Kaplan D.R., and Miller F.D. Signal transduction by the neurotrophin receptors. Curr. Opin. Cell Biol. 9 (1997) 213-221
29. Greco A., Fusetti L., Miranda C., Villa R., Zanotti S., Pagliardini S., and Pierotti M.A. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 16 (1998) 809-816
30. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., and Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 (1990) 557-563
31. Pierotti M.A., Santoro M., Jenkins R.B., Sozzi G., Bongarzone I., Grieco M., Monzini N., Miozzo M., Herrmann M.A., Fusco A., et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1616-1620
32. Sozzi G., Bongarzone I., Miozzo M., Borrello M.G., Blutti M.G., Pilotti S., Della Porta G., and Pierotti M.A. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer 9 (1994) 244-250
33. Klugbauer S., Demidchik E.P., Lengfelder E., and Rabes H.M. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res. 58 (1998) 198-203
34. Fugazzola L., Pierotti M.A., Vigano E., Pacini F., Vorontsova T.V., and Bongarzone I. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene 13 (1996) 1093-1097
35. Santoro M., Dathan N.A., Berlingieri M.T., Bongarzone I., Paulin C., Grieco M., Pierotti M.A., Vecchio G., and Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9 (1994) 509-516
36. Alberti L., Carniti C., Miranda C., Roccato E., and Pierotti M.A. RET and NTRK1 proto-oncogenes in human diseases. J. Cell. Physiol. 195 (2003) 168-186
37. Hamatani K., Eguchi H., Ito R., Mukai M., Takahashi K., Taga M., Imai K., Cologne J., Soda M., Arihiro K., Fujihara M., Abe K., Hayashi T., Nakashima M., Sekine I., Yasui W., Hayashi Y., and Nakachi K. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 68 (2008) 7176-7182
38. Fukushima T., Suzuki S., Mashiko M., Ohtake T., Endo Y., Takebayashi Y., Sekikawa K., Hagiwara K., and Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22 (2003) 6455-6457
39. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., and Sidransky D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95 (2003) 625-627
40. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J.A., and Nikiforov Y.E. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88 (2003) 5399-5404
41. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., Ohtsuru A., Saenko V.A., Kanematsu T., and Yamashita S. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88 (2003) 4393-4397
42. Frattini M., Ferrario C., Bressan P., Balestra D., De Cecco L., Mondellini P., Bongarzone I., Collini P., Gariboldi M., Pilotti S., Pierotti M.A., and Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 (2004) 7436-7440
43. Esapa C.T., Johnson S.J., Kendall-Taylor P., Lennard T.W., and Harris P.E. Prevalence of Ras mutations in thyroid neoplasia. Clin. Endocrinol. 50 (1999) 529-535
44. Bongarzone I., Fugazzola L., Vigneri P., Mariani L., Mondellini P., Pacini F., Basolo F., Pinchera A., Pilotti S., and Pierotti M.A. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 81 (1996) 2006-2009
45. Tallini G., and Asa S.L. RET oncogene activation in papillary thyroid carcinoma. Adv. Anat. Pathol. 8 (2001) 345-354
46. Chua E.L., Wu W.M., Tran K.T., McCarthy S.W., Lauer C.S., Dubourdieu D., Packham N., O'Brien C.J., Turtle J.R., and Dong Q. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J. Clin. Endocrinol. Metab. 85 (2000) 2733-2739
47. Learoyd D.L., Messina M., Zedenius J., Guinea A.I., Delbridge L.W., and Robinson B.G. RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 83 (1998) 3631-3635
48. Nakachi K., Hayashi T., Hamatani K., Eguchi H., and Kusunoki Y. Sixty years of follow-up of Hiroshima and Nagasaki survivors: current progress in molecular epidemiology studies. Mutat. Res. 659 (2008) 109-117
49. Kazakov V.S., Demidchik E.P., and Astakhova L.N. Thyroid cancer after Chernobyl. Nature 359 (1992) 21
50. Astakhova L.N., Anspaugh L.R., Beebe G.W., Bouville A., Drozdovitch V.V., Garber V., Gavrilin Y.I., Khrouch V.T., Kuvshinnikov A.V., Kuzmenkov Y.N., Minenko V.P., Moschik K.V., Nalivko A.S., Robbins J., Shemiakina E.V., Shinkarev S., Tochitskaya S.I., and Waclawiw M.A. Chernobyl-related thyroid cancer in children of Belarus: a case-control study. Radiat. Res. 150 (1998) 349-356
51. Imaizumi M., Usa T., Tominaga T., Neriishi K., Akahoshi M., Nakashima E., Ashizawa K., Hida A., Soda M., Fujiwara S., Yamada M., Ejima E., Yokoyama N., Okubo M., Sugino K., Suzuki G., Maeda R., Nagataki S., and Eguchi K. Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA 295 (2006) 1011-1022
52. Pierotti M.A., Bongarzone I., Borello M.G., Greco A., Pilotti S., and Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer 16 (1996) 1-14
53. Bullerdiek J., Raabe G., Boschen C., and Bartnitzke S. Translocation (3;8;8)(p22 or p23;p23;q12) in a case of pleomorphic adenoma: similarity to a primary cytogenetic abnormality detected in an endometrial adenocarcinoma. Cancer Genet. Cytogenet. 27 (1987) 177-180
54. Waldron C. Mixed tumor (pleomorphic adenoma and myoepithelioma). In: Gnepp G.E.P.A.D. (Ed). Surgical Pathology of the Salivary Glands. (1991), W.B. Saunders Co., Philadelphia 165-184
55. Shah J.P., and Ihde J.K. Salivary gland tumors. Curr. Probl. Surg. 27 (1990) 775-883
56. Stenman G. Fusion oncogenes and tumor type specificity-insights from salivary gland tumors. Semin. Cancer Biol. 15 (2005) 224-235
57. Bullerdiek J., Haubrich J., Meyer K., and Bartnitzke S. Translocation t(11;19)(q21;p13.1) as the sole chromosome abnormality in a cystadenolymphoma (Warthin's tumor) of the parotid gland. Cancer Genet. Cytogenet. 35 (1988) 129-132
58. Bullerdiek J., Wobst G., Meyer-Bolte K., Chilla R., Haubrich J., Thode B., and Bartnitzke S. Cytogenetic subtyping of 220 salivary gland pleomorphic adenomas: correlation to occurrence, histological subtype, and in vitro cellular behavior. Cancer Genet. Cytogenet. 65 (1993) 27-31
59. Kas K., Voz M.L., Roijer E., Astrom A.K., Meyen E., Stenman G., and Van de Ven W.J. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat. Genet. 15 (1997) 170-174
60. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science (New York, N.Y) 303 (2004) 1483-1487
61. Hensen K., Van Valckenborgh I.C., Kas K., Van de Ven W.J., and Voz M.L. The tumorigenic diversity of the three PLAG family members is associated with different DNA binding capacities. Cancer Res. 62 (2002) 1510-1517
62. de Jong B., Molenaar I.M., Leeuw J.A., Idenberg V.J., and Oosterhuis J.W. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet. Cytogenet. 21 (1986) 165-169
63. Meloni A.M., Dobbs R.M., Pontes J.E., and Sandberg A.A. Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet. Cytogenet. 65 (1993) 1-6
64. Meloni A.M., Sandberg A.A., Pontes J.E., and Dobbs Jr. R.M. Translocation (X;1)(p11.2;q21). A subtype of renal adenocarcinomas. Cancer Genet. Cytogenet. 63 (1992) 100-101
65. Shipley J.M., Birdsall S., Clark J., Crew J., Gill S., Linehan M., Gnarra J., Fisher S., Craig I.W., and Cooper C.S. Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case. Cytogenet. Cell Genet. 71 (1995) 280-284
66. Tonk V., Wilson K.S., Timmons C.F., Schneider N.R., and Tomlinson G.E. Renal cell carcinoma with translocation (X;1). Further evidence for a cytogenetically defined subtype. Cancer Genet. Cytogenet. 81 (1995) 72-75
67. Beckmann H., Su L.K., and Kadesch T. TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev. 4 (1990) 167-179
68. Henthorn P.S., Stewart C.C., Kadesch T., and Puck J.M. The gene encoding human TFE3, a transcription factor that binds the immunoglobulin heavy-chain enhancer, maps to Xp11.22. Genomics 11 (1991) 374-378
69. Sidhar S.K., Clark J., Gill S., Hamoudi R., Crew A.J., Gwilliam R., Ross M., Linehan W.M., Birdsall S., Shipley J., and Cooper C.S. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Mol. Genet. 5 (1996) 1333-1338
70. Sudol M. From Src homology domains to other signaling modules: proposal of the 'protein recognition code'. Oncogene 17 (1998) 1469-1474
71. Ren R., Mayer B.J., Cicchetti P., and Baltimore D. Identification of a ten-amino acid proline-rich SH3 binding site. Science (New York, N.Y) 259 (1993) 1157-1161
72. Weterman M.A., Wilbrink M., and Geurts van Kessel A. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 15294-15298
73. Weterman M.J., van Groningen J.J., Jansen A., and van Kessel A.G. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. Oncogene 19 (2000) 69-74
74. Clark J., Lu Y.J., Sidhar S.K., Parker C., Gill S., Smedley D., Hamoudi R., Linehan W.M., Shipley J., and Cooper C.S. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15 (1997) 2233-2239
75. Skalsky Y.M., Ajuh P.M., Parker C., Lamond A.I., Goodwin G., and Cooper C.S. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors. Oncogene 20 (2001) 178-187
76. Odero M.D., Grand F.H., Iqbal S., Ross F., Roman J.P., Vizmanos J.L., Andrieux J., Lai J.L., Calasanz M.J., and Cross N.C. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia 19 (2005) 245-252
77. Schoenmakers E.F., Wanschura S., Mols R., Bullerdiek J., Van den Berghe H., and Van de Ven W.J. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat. Genet. 10 (1995) 436-444
78. Ashar H.R., Fejzo M.S., Tkachenko A., Zhou X., Fletcher J.A., Weremowicz S., Morton C.C., and Chada K. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82 (1995) 57-65
79. Agresti A., and Bianchi M.E. HMGB proteins and gene expression. Curr. Opin. Genet. Dev. 13 (2003) 170-178
80. Geurts J.M., Schoenmakers E.F., Roijer E., Stenman G., and Van de Ven W.J. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res. 57 (1997) 13-17
81. Geurts J.M., Schoenmakers E.F., Roijer E., Astrom A.K., Stenman G., and van de Ven W.J. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 16 (1998) 865-872
82. Fedele M., Battista S., Kenyon L., Baldassarre G., Fidanza V., Klein-Szanto A.J., Parlow A.F., Visone R., Pierantoni G.M., Outwater E., Santoro M., Croce C.M., and Fusco A. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21 (2002) 3190-3198
83. Battista S., Fidanza V., Fedele M., Klein-Szanto A.J., Outwater E., Brunner H., Santoro M., Croce C.M., and Fusco A. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res. 59 (1999) 4793-4797
84. Baldassarre G., Fedele M., Battista S., Vecchione A., Klein-Szanto A.J., Santoro M., Waldmann T.A., Azimi N., Croce C.M., and Fusco A. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7970-7975
85. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., and Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84 (1996) 587-597
86. Gemmill R.M., West J.D., Boldog F., Tanaka N., Robinson L.J., Smith D.I., Li F., and Drabkin H.A. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9572-9577
87. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
88. Lewis B.P., Burge C.B., and Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120 (2005) 15-20
89. Mayr C., Hemann M.T., and Bartel D.P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (New York, N.Y) 315 (2007) 1576-1579
90. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., and Fletcher J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (New York, N.Y) 289 (2000) 1357-1360
91. Gimm O. Thyroid cancer. Cancer Lett. 163 (2001) 143-156
92. Nikiforova M.N., and Nikiforov Y.E. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev. Mol. Diagn. 8 (2008) 83-95
93. Puppin C., Presta I., D'Elia A.V., Tell G., Arturi F., Russo D., Filetti S., and Damante G. Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter. Mol. Cell. Endocrinol. 214 (2004) 117-125
94. Tontonoz P., and Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Ann. Rev. Biochem. 77 (2008) 289-312
95. Lui W.O., Foukakis T., Liden J., Thoppe S.R., Dwight T., Hoog A., Zedenius J., Wallin G., Reimers M., and Larsson C. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene. Oncogene 24 (2005) 1467-1476
96. Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn II G.W., Tallini G., Kroll T.G., and Nikiforov Y.E. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88 (2003) 2318-2326
97. Foukakis T., Au A.Y., Wallin G., Geli J., Forsberg L., Clifton-Bligh R., Robinson B.G., Lui W.O., Zedenius J., and Larsson C. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. J. Clin. Endocrinol. Metab. 91 (2006) 1143-1149
98. French C.A., Miyoshi I., Aster J.C., Kubonishi I., Kroll T.G., Dal Cin P., Vargas S.O., Perez-Atayde A.R., and Fletcher J.A. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am. J. Pathol. 159 (2001) 1987-1992
99. French C.A., Miyoshi I., Kubonishi I., Grier H.E., Perez-Atayde A.R., and Fletcher J.A. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 63 (2003) 304-307
100. French C.A. Molecular pathology of NUT midline carcinomas. J. Clin. Pathol. (2008)
101. Dey A., Ellenberg J., Farina A., Coleman A.E., Maruyama T., Sciortino S., Lippincott-Schwartz J., and Ozato K. A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. Mol. Cell. Biol. 20 (2000) 6537-6549
102. Maruyama T., Farina A., Dey A., Cheong J., Bermudez V.P., Tamura T., Sciortino S., Shuman J., Hurwitz J., and Ozato K. A mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase. Mol. Cell. Biol. 22 (2002) 6509-6520
103. Farina A., Hattori M., Qin J., Nakatani Y., Minato N., and Ozato K. Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol. Cell. Biol. 24 (2004) 9059-9069
104. Dey A., Chitsaz F., Abbasi A., Misteli T., and Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8758-8763
105. Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., and Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19 (2005) 523-534
106. French C.A., Ramirez C.L., Kolmakova J., Hickman T.T., Cameron M.J., Thyne M.E., Kutok J.L., Toretsky J.A., Tadavarthy A.K., Kees U.R., Fletcher J.A., and Aster J.C. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27 (2008) 2237-2242
107. Oberman H.A. Secretory carcinoma of the breast in adults. Am. J. Surg. Pathol. 4 (1980) 465-470
108. Tognon C., Knezevich S.R., Huntsman D., Roskelley C.D., Melnyk N., Mathers J.A., Becker L., Carneiro F., MacPherson N., Horsman D., Poremba C., and Sorensen P.H. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2 (2002) 367-376
109. Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C., Bray-Ward P., Morgan E., Raimondi S.C., Rowley J.D., and Gilliland D.G. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4917-4921
110. Papadopoulos P., Ridge S.A., Boucher C.A., Stocking C., and Wiedemann L.M. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 55 (1995) 34-38
111. Golub T.R., Goga A., Barker G.F., Afar D.E., McLaughlin J., Bohlander S.K., Rowley J.D., Witte O.N., and Gilliland D.G. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol. 16 (1996) 4107-4116
112. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffe M., Berthou C., Lessard M., Berger R., Ghysdael J., and Bernard O.A. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science (New York, NY) 278 (1997) 1309-1312
113. Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J., Philip P., Monpoux F., Van Rompaey L., Baens M., Van den Berghe H., and Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90 (1997) 2535-2540
114. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria Jr. R., Marynen P., and Gilliland D.G. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17 (1998) 5321-5333
115. Cazzaniga G., Tosi S., Aloisi A., Giudici G., Daniotti M., Pioltelli P., Kearney L., and Biondi A. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 94 (1999) 4370-4373
116. Iijima Y., Ito T., Oikawa T., Eguchi M., Eguchi-Ishimae M., Kamada N., Kishi K., Asano S., Sakaki Y., and Sato Y. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation. Blood 95 (2000) 2126-2131
117. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
118. Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., Taniwaki M., Matsuda A., and Bessho M. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res. 61 (2001) 8371-8374
119. Bohlander S.K. ETV6: a versatile player in leukemogenesis. Semin. Cancer Biol. 15 (2005) 162-174
120. Wang L.C., Swat W., Fujiwara Y., Davidson L., Visvader J., Kuo F., Alt F.W., Gilliland D.G., Golub T.R., and Orkin S.H. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 12 (1998) 2392-2402
121. Kaplan D.R., and Miller F.D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10 (2000) 381-391
122. Knezevich S.R., McFadden D.E., Tao W., Lim J.F., and Sorensen P.H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet. 18 (1998) 184-187
123. Lannon C.L., and Sorensen P.H. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin. Cancer Biol. 15 (2005) 215-223
124. Jin W., Kim B.C., Tognon C., Lee H.J., Patel S., Lannon C.L., Maris J.M., Triche T.J., Sorensen P.H., and Kim S.J. The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16239-16244
125. Davis B.N., Hilyard A.C., Lagna G., and Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature (2008)
126. Herz H., Cooke B., and Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann. Oncol. 11 (2000) 1343-1347
127. de Bree E., Askoxylakis J., Giannikaki E., Chroniaris N., Sanidas E., and Tsiftsis D.D. Secretory carcinoma of the male breast. Ann. Surg. Oncol. 9 (2002) 663-667
128. Jin W., Yun C., Hobbie A., Martin M.J., Sorensen P.H., and Kim S.J. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res. 67 (2007) 3192-3200
129. Li Z., Tognon C.E., Godinho F.J., Yasaitis L., Hock H., Herschkowitz J.I., Lannon C.L., Cho E., Kim S.J., Bronson R.T., Perou C.M., Sorensen P.H., and Orkin S.H. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 12 (2007) 542-558
130. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. 8 (2008) 497-511
131. Lin B., Ferguson C., White J.T., Wang S., Vessella R., True L.D., Hood L., and Nelson P.S. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59 (1999) 4180-4184
132. Afar D.E., Vivanco I., Hubert R.S., Kuo J., Chen E., Saffran D.C., Raitano A.B., and Jakobovits A. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61 (2001) 1686-1692
133. Vaarala M.H., Porvari K., Kyllonen A., Lukkarinen O., and Vihko P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer 94 (2001) 705-710
134. Lapointe J., Kim Y.H., Miller M.A., Li C., Kaygusuz G., van de Rijn M., Huntsman D.G., Brooks J.D., and Pollack J.R. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Path. 20 (2007) 467-473
135. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., and Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (New York, N.Y) 310 (2005) 644-648
136. Cerveira N., Ribeiro F.R., Peixoto A., Costa V., Henrique R., Jeronimo C., and Teixeira M.R. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia (New York, N.Y) 8 (2006) 826-832
137. Clark J., Merson S., Jhavar S., Flohr P., Edwards S., Foster C.S., Eeles R., Martin F.L., Phillips D.H., Crundwell M., Christmas T., Thompson A., Fisher C., Kovacs G., and Cooper C.S. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26 (2007) 2667-2673
138. Hermans K.G., van Marion R., van Dekken H., Jenster G., van Weerden W.M., and Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66 (2006) 10658-10663
139. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., Peltola M., Smit F., Verhaegh G., Schalken J., Nees M., and Kallioniemi O. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 66 (2006) 10242-10246
140. Rajput A.B., Miller M.A., De Luca A., Boyd N., Leung S., Hurtado-Coll A., Fazli L., Jones E.C., Palmer J.B., Gleave M.E., Cox M.E., and Huntsman D.G. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 60 (2007) 1238-1243
141. Soller M.J., Isaksson M., Elfving P., Soller W., Lundgren R., and Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45 (2006) 717-719
142. Yoshimoto M., Joshua A.M., Chilton-Macneill S., Bayani J., Selvarajah S., Evans A.J., Zielenska M., and Squire J.A. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (New York, N.Y) 8 (2006) 465-469
143. Wang J., Cai Y., Ren C., and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66 (2006) 8347-8351
144. Mertz K.D., Setlur S.R., Dhanasekaran S.M., Demichelis F., Perner S., Tomlins S., Tchinda J., Laxman B., Vessella R.L., Beroukhim R., Lee C., Chinnaiyan A.M., and Rubin M.A. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (New York, NY) 9 (2007) 200-206
145. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., Cao Q., Prensner J.R., Rubin M.A., Shah R.B., Mehra R., and Chinnaiyan A.M. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (New York, NY) 10 (2008) 177-188
146. Sun C., Dobi A., Mohamed A., Li H., Thangapazham R.L., Furusato B., Shaheduzzaman S., Tan S.H., Vaidyanathan G., Whitman E., Hawksworth D.J., Chen Y., Nau M., Patel V., Vahey M., Gutkind J.S., Sreenath T., Petrovics G., Sesterhenn I.A., McLeod D.G., and Srivastava S. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27 (2008) 5348-5353
147. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., Yu J., Wang L., Montie J.E., Rubin M.A., Pienta K.J., Roulston D., Shah R.B., Varambally S., Mehra R., and Chinnaiyan A.M. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 (2007) 595-599
148. Shaffer D.R., and Pandolfi P.P. Breaking the rules of cancer. Nat. Med. 12 (2006) 14-15
149. Tomlins S.A., Mehra R., Rhodes D.R., Smith L.R., Roulston D., Helgeson B.E., Cao X., Wei J.T., Rubin M.A., Shah R.B., and Chinnaiyan A.M. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66 (2006) 3396-3400
150. Han B., Mehra R., Dhanasekaran S.M., Yu J., Menon A., Lonigro R.J., Wang X., Gong Y., Wang L., Shankar S., Laxman B., Shah R.B., Varambally S., Palanisamy N., Tomlins S.A., Kumar-Sinha C., and Chinnaiyan A.M. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 68 (2008) 7629-7637
151. Helgeson B.E., Tomlins S.A., Shah N., Laxman B., Cao Q., Prensner J.R., Cao X., Singla N., Montie J.E., Varambally S., Mehra R., and Chinnaiyan A.M. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68 (2008) 73-80
152. Hermans K.G., Bressers A.A., van der Korput H.A., Dits N.F., Jenster G., and Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 68 (2008) 3094-3098
153. Mehra R., Tomlins S.A., Yu J., Cao X., Wang L., Menon A., Rubin M.A., Pienta K.J., Shah R.B., and Chinnaiyan A.M. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68 (2008) 3584-3590
154. Cai C., Hsieh C.L., Omwancha J., Zheng Z., Chen S.Y., Baert J.L., and Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. (Baltimore, Md) 21 (2007) 1835-1846
155. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., and Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007) 561-566
156. Pollmann M., Parwaresch R., Adam-Klages S., Kruse M.L., Buck F., and Heidebrecht H.J. Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp. Cell Res. 312 (2006) 3241-3251
157. Choi Y.L., Takeuchi K., Soda M., Inamura K., Togashi Y., Hatano S., Enomoto M., Hamada T., Haruta H., Watanabe H., Kurashina K., Hatanaka H., Ueno T., Takada S., Yamashita Y., Sugiyama Y., Ishikawa Y., and Mano H. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68 (2008) 4971-4976
158. Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., Enomoto M., Takada S., Yamashita Y., Satoh Y., Okumura S., Nakagawa K., Ishikawa Y., and Mano H. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res. 14 (2008) 6618-6624
159. Fukuyoshi Y., Inoue H., Kita Y., Utsunomiya T., Ishida T., and Mori M. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br. J. Cancer 98 (2008) 1536-1539
160. Inamura K., Takeuchi K., Togashi Y., Nomura K., Ninomiya H., Okui M., Satoh Y., Okumura S., Nakagawa K., Soda M., Choi Y.L., Niki T., Mano H., and Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J. Thorac. Oncol. 3 (2008) 13-17
161. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., and Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (New York, N.Y) 263 (1994) 1281-1284
162. Lamant L., Dastugue N., Pulford K., Delsol G., and Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93 (1999) 3088-3095
163. Touriol C., Greenland C., Lamant L., Pulford K., Bernard F., Rousset T., Mason D.Y., and Delsol G. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95 (2000) 3204-3207
164. Colleoni G.W., Bridge J.A., Garicochea B., Liu J., Filippa D.A., and Ladanyi M. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am. J. Pathol. 156 (2000) 781-789
165. Ma Z., Cools J., Marynen P., Cui X., Siebert R., Gesk S., Schlegelberger B., Peeters B., De Wolf-Peeters C., Wlodarska I., and Morris S.W. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95 (2000) 2144-2149
166. Trinei M., Lanfrancone L., Campo E., Pulford K., Mason D.Y., Pelicci P.G., and Falini B. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 60 (2000) 793-798
167. Hernandez L., Pinyol M., Hernandez S., Bea S., Pulford K., Rosenwald A., Lamant L., Falini B., Ott G., Mason D.Y., Delsol G., and Campo E. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94 (1999) 3265-3268
168. Shinmura K., Kageyama S., Tao H., Bunai T., Suzuki M., Kamo T., Takamochi K., Suzuki K., Tanahashi M., Niwa H., Ogawa H., and Sugimura H. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer (Amsterdam, Netherlands) (2008)
169. Perner S., Wagner P.L., Demichelis F., Mehra R., Lafargue C.J., Moss B.J., Arbogast S., Soltermann A., Weder W., Giordano T.J., Beer D.G., Rickman D.S., Chinnaiyan A.M., Moch H., and Rubin M.A. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (New York, N.Y) 10 (2008) 298-302
170. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.L., Polakiewicz R.D., Rush J., and Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007) 1190-1203
171. Maher C.A., Kumar-Sinha C., Cao X., Kalyana-Sundaram S., Han B., Jing X., Sam L., Barrette T., Palanisamy N., and Chinnaiyan A.M. Transcriptome sequencing to detect gene fusions in cancer. Nature (2009)
172. Ayton P.M., and Cleary M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20 (2001) 5695-5707
173. Collins E.C., and Rabbitts T.H. The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism. Trends Mol. Med. 8 (2002) 436-442
174. Daser A., and Rabbitts T.H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev. 18 (2004) 965-974
175. Schumacher A., and Magnuson T. Murine polycomb- and trithorax-group genes regulate homeotic pathways and beyond. Trends Genet. 13 (1997) 167-170
176. Maconochie M., Nonchev S., Morrison A., and Krumlauf R. Paralogous Hox genes: function and regulation. Annu. Rev. Genet. 30 (1996) 529-556
177. Look A.T. Oncogenic transcription factors in the human acute leukemias. Science (New York, NY) 278 (1997) 1059-1064
178. Ayton P.M., and Cleary M.L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17 (2003) 2298-2307
179. Hsu K., and Look A.T. Turning on a dimer: new insights into MLL chimeras. Cancer Cell 4 (2003) 81-83
180. Zeleznik-Le N.J., Harden A.M., and Rowley J.D. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10610-10614
181. Nakamura T., Mori T., Tada S., Krajewski W., Rozovskaia T., Wassell R., Dubois G., Mazo A., Croce C.M., and Canaani E. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell 10 (2002) 1119-1128
182. So C.W., Lin M., Ayton P.M., Chen E.H., and Cleary M.L. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4 (2003) 99-110
183. Milne T.A., Martin M.E., Brock H.W., Slany R.K., and Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 65 (2005) 11367-11374
184. Dorrance A.M., Liu S., Yuan W., Becknell B., Arnoczky K.J., Guimond M., Strout M.P., Feng L., Nakamura T., Yu L., Rush L.J., Weinstein M., Leone G., Wu L., Ferketich A., Whitman S.P., Marcucci G., and Caligiuri M.A. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J. Clin. Invest. 116 (2006) 2707-2716
185. Sandberg A.A. The chromosomes and causation of human cancer and leukemia. Cancer Res. 26 (1966) 2064-2081
186. DeGrouchy J. Chromosomes in neoplastic tissues. In: Neel J.C.J. (Ed). Proceedings of the Third International Congress of Human Genetics (1967), Johns Hopkins Univ. Press, Chicago
187. Aguilera A., and Gomez-Gonzalez B. Genome instability: a mechanistic view of its causes and consequences. Nat. Rev., Genet. 9 (2008) 204-217
188. Halazonetis T.D., Gorgoulis V.G., and Bartek J. An oncogene-induced DNA damage model for cancer development. Science (New York, N.Y) 319 (2008) 1352-1355
189. Zhang N., Ge G., Meyer R., Sethi S., Basu D., Pradhan S., Zhao Y.J., Li X.N., Cai W.W., El-Naggar A.K., Baladandayuthapani V., Kittrell F.S., Rao P.H., Medina D., and Pati D. Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 13033-13038
190. Sotillo R., Hernando E., Diaz-Rodriguez E., Teruya-Feldstein J., Cordon-Cardo C., Lowe S.W., and Benezra R. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11 (2007) 9-23
191. Gorunova L., Hoglund M., Andren-Sandberg A., Dawiskiba S., Jin Y., Mitelman F., and Johansson B. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 23 (1998) 81-99
192. Mitelman F., Johansson B., and Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat. Genet. 36 (2004) 331-334
193. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., and Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY) 6 (2004) 1-6
194. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Barrette T.R., Ghosh D., and Chinnaiyan A.M. Mining for regulatory programs in the cancer transcriptome. Nat. Genet. 37 (2005) 579-583
195. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., Barrette T.R., Anstet M.J., Kincead-Beal C., Kulkarni P., Varambally S., Ghosh D., and Chinnaiyan A.M. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York, NY) 9 (2007) 166-180
196. Rhodes D.R., Kalyana-Sundaram S., Tomlins S.A., Mahavisno V., Kasper N., Varambally R., Barrette T.R., Ghosh D., Varambally S., and Chinnaiyan A.M. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia (New York, NY) 9 (2007) 443-454
197. Jacquinet E., Rao N.V., Rao G.V., Zhengming W., Albertine K.H., and Hoidal J.R. Cloning and characterization of the cDNA and gene for human epitheliasin. Eur. J. Biochem./FEBS 268 (2001) 2687-2699
198. Takahara T., Tasic B., Maniatis T., Akanuma H., and Yanagisawa S. Delay in synthesis of the 3′ splice site promotes trans-splicing of the preceding 5′ splice site. Mol. Cell 18 (2005) 245-251
199. Communi D., Suarez-Huerta N., Dussossoy D., Savi P., and Boeynaems J.M. Cotranscription and intergenic splicing of human P2Y11 and SSF1 genes. J. Biol. Chem. 276 (2001) 16561-16566
200. Koontz J.I., Soreng A.L., Nucci M., Kuo F.C., Pauwels P., van Den Berghe H., Dal Cin P., Fletcher J.A., and Sklar J. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6348-6353
201. Li H., Wang J., Mor G., and Sklar J. A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science (New York, NY) 321 (2008) 1357-1361
202. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., and Burge C.B. Prediction of mammalian microRNA targets. Cell 115 (2003) 787-798